CLRB logo

Cellectar Biosciences, Inc.

CLRB
Healthcare|Biotechnology|US
$1.25
+0.10 (+8.70%)
DCF Value
$4.39
Tangible Book / Share
$2.44
Cash / Share
$2.78
Next Earnings Report
Mar 11, 2027
EPS est. -$0.53 · Revenue est. $24.9M
Financing Filings (last 12 months)
5
Shelf registrations / offering prospectuses — latest Jun 2, 2026 (424B3). Possible dilution.

Upcoming Data Readouts (3)

Jun 2027
Est. completion
P1High-Grade Glioma
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
NCT05610891n=50
Jun 2027
Est. completion
P1Pediatric Solid Tumor
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
NCT03478462n=30
Feb 2028
Est. completion
P1Breast Cancer
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
NCT07311993n=60

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Jun 2026
P2
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
NCT02952508

Recent Press Releases

Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and Exposition
Nov 4, 2026 · GlobeNewsWire
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026
Nov 2, 2026 · GlobeNewsWire
Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131
Oct 27, 2026 · GlobeNewsWire
Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia
Oct 15, 2026 · GlobeNewsWire
Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia
Sep 29, 2026 · GlobeNewsWire
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Aug 13, 2026 · GlobeNewsWire

SEC Filings (80)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Aug 14, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 14, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 14, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 14, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 13, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 13, 20268-KMaterial eventDocumentIndex
Aug 13, 202610-QQuarterly reportDocumentIndex
Aug 4, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jul 10, 20268-KMaterial eventDocumentIndex
Jun 5, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jun 2, 2026424B3Offering prospectusDocumentIndex
Jun 1, 2026EFFECTDocumentIndex
May 29, 2026S-1/AIPO / offering registrationDocumentIndex
May 28, 2026DEFA14AProxy / shareholder voteDocumentIndex
May 28, 2026DEF 14AProxy / shareholder voteDocumentIndex
May 19, 2026S-1IPO / offering registrationDocumentIndex
May 18, 2026PRE 14AProxy / shareholder voteDocumentIndex
May 18, 20268-KMaterial eventDocumentIndex
May 14, 20268-KMaterial eventDocumentIndex
May 14, 202610-QQuarterly reportDocumentIndex
May 11, 2026SC 13GPassive 5%+ stakeDocumentIndex
May 8, 20268-KMaterial eventDocumentIndex
May 6, 2026424B5Offering prospectusDocumentIndex
Apr 30, 202610-K/AAnnual reportDocumentIndex
Mar 4, 20268-KMaterial eventDocumentIndex
Mar 4, 202610-KAnnual reportDocumentIndex
Feb 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 10, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 4, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Nov 21, 2025424B3Offering prospectusDocumentIndex
Nov 14, 2025SC 13GPassive 5%+ stakeDocumentIndex
Nov 13, 20258-KMaterial eventDocumentIndex
Nov 13, 202510-QQuarterly reportDocumentIndex
Oct 20, 2025S-1IPO / offering registrationDocumentIndex
Oct 10, 20258-KMaterial eventDocumentIndex
Oct 6, 20258-KMaterial eventDocumentIndex
Aug 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 20258-KMaterial eventDocumentIndex